Fair point — cost is a real barrier early on.But right now, we don’t have a large number of physicians trained yet, so volume is still building.There’s definitely a large global patient population who could afford private treatment — pancreatic cancer affects over 500,000 people annually, with about 30% being locally advanced, and a decent proportion in developed countries have private insurance or means to self-pay (especially for life-extending therapies like this).You can already see progress:
Germany: fully funded G-BA trial
UK: BUPA and private insurers covering
Israel: insurer approval in place
Saudi Arabia: full reimbursement once launched
Reimbursement is happening — rollout just takes time.
OSL Price at posting:
0.4¢ Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)